Galapagos - GLPG Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings or view top-rated stocks.

7 brokers have issued twelve-month price targets for Galapagos' stock. Their GLPG share price forecasts range from $55.00 to $70.00. On average, they expect the company's share price to reach $62.75 in the next year. This suggests a possible upside of 47.7% from the stock's current price.
View analysts price targets for GLPG or view top-rated stocks among Wall Street analysts.

Galapagos' stock was trading at $55.13 at the beginning of the year. Since then, GLPG stock has decreased by 22.9% and is now trading at $42.49.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our GLPG earnings forecast.

Galapagos NV (NASDAQ:GLPG) announced its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.48. The biotechnology company had revenue of $146.62 million for the quarter, compared to the consensus estimate of $95.44 million. Galapagos had a negative net margin of 16.90% and a negative trailing twelve-month return on equity of 3.02%.

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (5.43%), Driehaus Capital Management LLC (0.78%), Prosight Management LP (0.56%), Jennison Associates LLC (0.46%), Renaissance Technologies LLC (0.38%) and Hudson Bay Capital Management LP (0.33%).

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLPG stock can currently be purchased for approximately $42.49.

Galapagos (NASDAQ:GLPG) has a market capitalization of $2.79 billion and generates $573.66 million in revenue each year.

The company employs 1,309 workers across the globe.

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901.